SPAGO logo

Spago Nanomedical AB (publ) Stock Price

OM:SPAGO Community·SEK 79.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

SPAGO Share Price Performance

SEK 0.12
-0.08 (-40.25%)
SEK 0.12
-0.08 (-40.25%)
Price SEK 0.12

SPAGO Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with medium-low risk.

6 Risks
1 Reward

Spago Nanomedical AB (publ) Key Details

SEK 4.4m

Revenue

SEK 12.0m

Cost of Revenue

-SEK 7.6m

Gross Profit

SEK 18.3m

Other Expenses

-SEK 25.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.039
-173.31%
-591.17%
0%
View Full Analysis

About SPAGO

Founded
1999
Employees
5
CEO
Mats Hansen
WebsiteView website
spagonanomedical.se

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.

Recent SPAGO News & Updates

Recent updates

No updates